Bortezomib Sensitivity in Lung Cancer Cells
Author Information
Author(s): Voortman Jens, Chęcińska Agnieszka, Giaccone Giuseppe
Primary Institution: VU University Medical Center
Hypothesis
The sensitivity of non-small cell lung cancer (NSCLC) cells to bortezomib is determined by their proteasomal and apoptotic phenotypes.
Conclusion
Successful treatment strategies using proteasome inhibitors in NSCLC must address both apoptosis resistance and proteasomal resistance in individual cancer cells.
Supporting Evidence
- NSCLC cell lines showed different sensitivity to bortezomib, with IC50 values ranging from 5 to 83 nM.
- H460 cells were more susceptible to apoptosis induction by bortezomib than SW1573 cells.
- Overexpression of Bcl-2 in H460 cells decreased bortezomib-induced apoptosis.
Takeaway
Some lung cancer cells respond to a drug called bortezomib, but others don't because of differences in how they handle proteins and how they die.
Methodology
The study used MTT assays to determine growth inhibition and flow cytometry for apoptosis analysis in NSCLC cell lines treated with bortezomib.
Limitations
The study primarily focused on cell lines, which may not fully represent the complexity of tumor responses in patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website